1 - 10 of 19 articles
Patients diagnosed with radioiodine refractory thyroid cancer (RAIR‐TC) are not amenable to novel 131I therapy due to the reduced expression of sodium iodide symporter (Na+/I‐ symporter, NIS) and/or the impairment of NIS trafficking to the plasma membrane. RAIR‐TC patients have a relatively poor...
Bladder cancer (BC) outcomes are unacceptably poor. In Australia, BC survival is actually deteriorating. There is an urgent need to improve outcomes in BC patients, which requires a multipronged approach. One area deserving closer scrutiny is radical cystectomy. Audit is necessary to identify...
Historically, the majority of oncology clinical trials are conducted in Western Europe and North America. Globalization of drug development has resulted in sponsors shifting their focus to the Asia‐Pacific region. In Malaysia, implementation of various government policies to promote clinical...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.